The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer—particularly those with specific HER2 mutations—with manageable side ...
Apr 28, 2025
0
20
A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK. This drug is designed to help adults with certain types of advanced cancer that cannot be removed by surgery, or which ...
Apr 15, 2025
0
24
The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor ...
Feb 3, 2025
0
22
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared ...
Jan 15, 2025
0
49
A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer patients taking antibody–drug conjugates (ADCs). This breakthrough method aims to offer a safer, ...
Nov 12, 2024
0
16
Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case report that signifies a potential breakthrough in the treatment of an aggressive type of prostate ...
Nov 5, 2024
0
72
Patients with advanced HER2-positive breast cancer very often develop brain metastases. When this happens, patients have low chances of surviving the next few years with existing therapies such as surgery and radiotherapy. ...
Oct 4, 2024
0
51
A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2-positive breast cancer. ...
Sep 13, 2024
0
74
A new editorial paper titled "HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity" has been published in Oncotarget.
Jul 16, 2024
0
38
In an editorial, published in Oncoscience titled, "Entering the golden age for antibody-drug conjugates in gynecologic cancer," researchers Michelle Greenman, Blair McNamara, Levent Mutlu, and Alessandro D. Santin from Yale ...
Jul 15, 2024
0
28
